JACC: Advances (Oct 2024)

Challenges and Priorities for Children With Congenital Valvar Heart Disease

  • Holly Bauser-Heaton, MD, PhD,
  • Oliver M. Barry, MD,
  • Sophie C. Hofferberth, MD,
  • Justin T. Tretter, MD,
  • Michael Ma, MD,
  • Andrew Goldstone, MD,
  • Aimee Armstrong, MD,
  • Thomas K. Jones, MD,
  • Ajit Yoganathan, PhD,
  • Pedro del Nido, MD

Journal volume & issue
Vol. 3, no. 10
p. 101191

Abstract

Read online

The Heart Valve Collaboratory is a multidisciplinary, patient-centered community of stakeholders addressing complex problems and embracing innovation to help patients with heart valve disease achieve their fullest potential for health. The Scientific Council is composed of cardiologists, surgeons, ex-officio representatives of the Food and Drug Administration and Centers for Medicare and Medicaid Services, National Heart Lung Blood Institute, and representatives from industry partners. In October 2022, this group convened a workshop that included experts from stakeholder groups to address the unmet and clinical needs of patients with pediatric and congenital heart valve disease. The following document includes the discussion and summary of the current state of valve therapy and the needs being addressed for valve development.

Keywords